The content of this website is intended for United States audiences only.

Report an Adverse Event
/-/media/project/gileadclinicaltrial/header/arrow-right-img.svg

HIV Treatment and Cure Research

At Gilead, we seek to advance new treatment options that meet unmet needs for those living with HIV. Join a Gilead HIV trial to help further developments in treatment research.

HeroBanner

Featured Trials

WONDERS 2

Study of Oral Weekly Therapy Compared With Approved Daily Oral Therapy in People Diagnosed with HIV-1 Who Have Not Been Treated.

ISLEND-1

A Phase 3 Clinical Trial Evaluating a Switch to Weekly Oral Therapy in People with HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

ISLEND-2

A Phase 3 Clinical Trial Evaluating a Switch to Weekly Oral Therapy in People with HIV-1 Who Are Virologically Suppressed on Standard of Care
Virologically Suppressed HIV_Mobile

Purpose 4

Study in people who are Virally Suppressed. This study aims to understand the safety and efficacy of investigational antiretroviral therapies in patients who are currently suppressed on a complex regiment.
HIV Progress

Gilead's Clinical Trials Fuel Progress against HIV

Early on, HIV treatments were complex, burdensome, and could require more than 20 pills per day. Through advancements in research, treatment was able to be reduced to a couple of pills per day, a substantial improvement in HIV treatment. Our quest to improve HIV treatment options and expand our reach continues as we aim to pioneer and research long-acting treatments.
 
Find an HIV Trial
HIV Epidemic

Committed to Ending the HIV Epidemic

Although HIV is now considered a chronic, manageable disease, there is no cure. We are working to find a cure for HIV in our labs and with over 100 research partners. Gilead is also an integral part of the nationwide mission of Ending the HIV Epidemic (EHE), a federal effort designed to reduce new HIV infections by 90% by 2030.
 
Learn More

Voices in Our Communities

The power of many: HIV communities create lasting change

Beyond Clinical Trials: Working Together to Address Challenges in the HIV Space

At Gilead we believe it takes a combination of both science and social efforts to make impactful progress against the HIV epidemic. By working with and supporting advocates and organizations across the country, we can make strides toward reaching this collective goal. Learn about Gilead's support of groups taking steps towards change, from My Brother's Keeper in Mississippi to Arianna's Center in South Florida.
View Organizations
Voices in Our Communities

Completed and Ongoing Trials

View more

Explore Our Other HIV Research Areas

hiv treatment cure

HIV Prevention

For decades, Gilead has been at the forefront of HIV prevention, developing the first pre-exposure prophylaxis (PrEP) medication to help prevent HIV transmission. Gilead’s innovations continue today. Learn about Gilead’s HIV Prevention research efforts.
HIV in Children_Mobile

Children with HIV

An estimated 1.7 million children under the age of 15 live with HIV. Gilead is deeply committed to the discovery and development of urgently needed, age-appropriate treatments for children living with HIV. Learn more about Gilead’s work in Pediatric HIV research.

Your Questions Answered

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

YOUR QUESTIONS ANSWERED

FAQ Topic:
ALL Clinical Trial Basics Safety and Security Trial Terms Defined The Clinical Trial

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

All trials have different timelines due to various factors, such as the trial phase, study design, treatment duration or health condition being studied. During the consent process before enrolling, the research team will explain the specifics about the trial.
Due to the many differences in insurance plans across the country, coverage in clinical trials can vary. You will learn more about your options during pre-screening.
If you are living with a medical condition, joining a clinical trial may give you access to a new potential treatment before it is publicly available. Just as importantly, it can help researchers understand how this potential treatment affects the body and increase their knowledge about the disease and how to treat it. Participation can also play a vital role in helping others who have a similar condition, both now and in the future. Healthy volunteers in trials contribute to this medical progress as well by helping understand the effect of the potential treatment and any safety concerns.
As with all medical records, participant privacy and confidentiality in trials are protected by law. Once consent is signed, you will be given a trial code. Your trial records will not include your name or personal identity but will identify you with a trial code. This code can only be tracked back to you via a code key which is held by the responsible physician. Your name or personal identity will never be disclosed.
Yes, participants are volunteers and may withdraw from a clinical trial at any time.
A placebo is an inactive version of an intervention that is not intended to provide any medical benefit. It is designed to look the same as the active intervention, so the participant and research team do not know it is a placebo. The placebo is used by comparison to confirm any effects of the intervention being studied, if no approved intervention is available.
"Standard of care" is an intervention already approved for a specific health condition that is available publicly. Interventions in a clinical trial are still being tested to ensure safety and effectiveness.
Some clinical trials are designed to be "double blind" so both participants and researchers are unaware of which treatment group participants are assigned to. This prevents bias from affecting clinical trial data.
Your informed consent is required before being enrolled in a trial. This means you have been provided all relevant information about the study design, how you will participate, your right to withdraw at any time, study alternatives, your personal data protection and the associated risks and benefits. Informed consent is designed to protect patient safety and privacy.
Under FDA regulations, an Institutional Review Board (IRB) is a group that has been formally designated to review and monitor research at a hospital or institution involving human participants. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in, or disapprove research.
Participants are always welcome to visit their usual healthcare providers during a trial. Sometimes, it is important for healthcare providers to collaborate with the research team to ensure success.
After your participation ends, the study may continue for months or years. Once final results from all participants are compiled and analyzed, they are often published publicly. Clinical study report (CSR) synopses and plain language summaries (PLSs) may be made available for certain studies. Check with your clinical trial site or send an email to [email protected] to learn more.
There are a wide variety of professionals involved with any clinical trial, all of whom are vital to ensuring safety and success. The principal investigator, or PI, leads the trial and directs the team of doctors, nurses and other healthcare workers. The clinical trial coordinator manages day-to-day activities and is the main contact for participants. Many clinical trials also have an independent Data and Safety Monitoring Board (DSMB) who periodically reviews data to ensure participant safety, and sometimes effectiveness.
If you don’t qualify because you don’t meet the trial criteria, consider discussing other options with your healthcare provider or the patient’s physician would need to submit a managed access request based on the eligibility. Click here to learn more.